Archive · 1 Oct 2026
Hospital stocks face drug-pricing scrutiny as investors weigh risks
The Supreme Court questioned why some hospitals may charge much more for medicines than retailers do.
One example involved a cancer medicine costing Rs 2,700 for retailers but Rs 27,000 for a hospital patient.
This made investors worry that hospitals could earn less money from their pharmacies.
Hospital shares fell for a second day.
One analyst said pharmacies can provide 10-25% of a hospital’s revenue and profits.
Another analyst expects a possible 2-4% reduction in EBITDA if rules are limited.
A wider price cap could hurt earnings more.
The court has not made a final decision, so investors are waiting for clearer rules.
The Supreme Court questioned steep mark-ups on cancer drugs, including a reported Rs 27,000 hospital price versus Rs 2,700 for retailers.
Investors are concerned that future regulation could reduce hospital pharmacy income and overall profitability.
Pharmacy operations may contribute about 10-25% of hospital revenue and profitability, according to SBI Securities’ Sunny Agrawal.
Mirae Asset Sharekhan estimates a potential 2-4% EBITDA reduction in its base case, while a broader 16% cap could have a larger impact.
Analysts say the court’s comments are not a final order, and investors should await clarity on which medicines and margins might be regulated.
- Who
- The Supreme Court, hospital companies, investors, and analysts Sunny Agrawal of SBI Securities and Thomas V Abraham of Mirae Asset Sharekhan.
- What
- The Supreme Court questioned hospital medicine mark-ups, prompting a sell-off in hospital stocks and debate over whether to buy the decline or remain cautious.
- When
- The concerns and market reaction occurred this week, with hospital shares falling for a second consecutive day.
- Where
- The issue concerns hospital pharmacies and hospital stocks traded on Dalal Street.
- Why
- Investors fear that future limits on medicine mark-ups could reduce pharmacy income and hospital profitability.
Stay cautious
Consider limited-impact opportunities
Near-term investment approach
Stay cautious
Sunny Agrawal recommends remaining on the sidelines until the regulatory framework is clearer because pharmacy margins could come under pressure.
Consider limited-impact opportunities
Thomas V Abraham indicates the impact may be limited if any cap applies mainly to critical, life-saving drugs, though he does not treat the court’s comments as a final decision.
Potential earnings effect
Stay cautious
A broader restriction on medicine margins could materially reduce hospital profitability because pharmacies contribute significantly to revenue and profits.
Consider limited-impact opportunities
In the base case, the market expects a 2-4% EBITDA reduction, suggesting a potentially manageable impact if regulation is narrowly designed.
Scope of possible regulation
Stay cautious
A broad cap on hospital pharmacy margins, including a possible 16% limit over the price to retailer, could create a substantially larger earnings impact.
Consider limited-impact opportunities
Limiting measures to selected critical drugs could balance affordability with hospital operating efficiency and expansion needs.
- Example price difference
- A cancer drug was cited as costing Rs 27,000 at a hospital versus Rs 2,700 for retailers.
- Pharmacy contribution
- Hospital pharmacies may account for about 10-25% of hospital revenue and profitability.
- Base-case earnings impact
- Mirae Asset Sharekhan expects a possible 2-4% reduction in EBITDA from current estimates.
- Broader cap scenario
- A 16% cap over the price to retailer could create a substantially larger impact.
- Regulatory status
- The Supreme Court’s comments are observations, not a final regulatory order or verdict.
- Reporting limitation
- Hospitals generally do not disclose pharmacy revenue separately, making company-level impacts difficult to estimate.
- Key investor focus
- The impact will depend on whether regulation covers selected critical drugs or hospital pharmacy margins more broadly.